GALENA BIOPHARMA INC's ticker is GALEXXXX and the CUSIP is 363256108. A total of 89 filers reported holding GALENA BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $248,000 | -24.6% | 708,015 | +0.4% | 0.00% | – |
| Q2 2016 | $329,000 | -63.3% | 704,955 | +6.9% | 0.00% | -100.0% |
| Q1 2016 | $897,000 | +8.3% | 659,718 | +17.1% | 0.00% | 0.0% |
| Q4 2015 | $828,000 | -6.5% | 563,149 | +0.5% | 0.00% | 0.0% |
| Q3 2015 | $886,000 | -8.7% | 560,581 | -1.8% | 0.00% | 0.0% |
| Q2 2015 | $970,000 | +61.7% | 570,653 | +32.2% | 0.00% | 0.0% |
| Q1 2015 | $600,000 | +15.6% | 431,636 | +25.7% | 0.00% | 0.0% |
| Q4 2014 | $519,000 | -27.1% | 343,501 | -0.6% | 0.00% | 0.0% |
| Q3 2014 | $712,000 | -32.3% | 345,609 | +0.6% | 0.00% | 0.0% |
| Q2 2014 | $1,051,000 | +29.6% | 343,553 | +5.9% | 0.00% | 0.0% |
| Q1 2014 | $811,000 | -41.8% | 324,439 | +15.5% | 0.00% | -50.0% |
| Q4 2013 | $1,394,000 | +120.2% | 281,002 | +1.1% | 0.00% | +100.0% |
| Q3 2013 | $633,000 | +31.3% | 277,828 | +27.8% | 0.00% | 0.0% |
| Q2 2013 | $482,000 | – | 217,331 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hoxton Financial, Inc. | 50,000 | $74,000 | 0.04% |
| Alyeska Investment Group, L.P. | 1,593,277 | $2,342,000 | 0.02% |
| DUMONT & BLAKE INVESTMENT ADVISORS LLC | 31,000 | $46,000 | 0.02% |
| GROUP ONE TRADING, L.P. | 1,346,904 | $1,980,000 | 0.02% |
| Matisse Capital | 17,000 | $25,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 15,000 | $22,000 | 0.01% |
| SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) | 12,150 | $18,000 | 0.01% |
| EQUITEC SPECIALISTS, LLC | 19,700 | $29,000 | 0.01% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 153,375 | $225,000 | 0.00% |
| OPPENHEIMER & CO INC | 94,300 | $138,000 | 0.00% |